| Literature DB >> 26684634 |
James W Navalta1, Elizabeth A Fedor2, Mark A Schafer2, T Scott Lyons2, Ramires A Tibana3, Guilherme B Pereira3, Jonato Prestes3.
Abstract
The purpose of this investigation was to determine the lymphocyte subset response to 30 min of moderate treadmill exercise during caffeine supplemented (6.0 mg.kg(-1)) and placebo conditions in caffeine-naïve and -familiar individuals. Seventeen individuals participated (caffeine-familiar = 8, caffeine-naïve = 9) completing two exercise bouts (caffeine supplemented and placebo control) 48 h apart in a counterbalanced and double-blinded fashion. Individuals were classified as follows: caffeine-naive <50 mg.d(-1) and caffeine-familiar >200 mg.d(-1) Whole blood samples were obtained at rest, 30 min after caffeine or placebo ingestion, immediately following exercise, and 1 h post exercise. Blood was used to analyze apoptosis (annexin V) and cellular migration (CX3CR1) responses in lymphocyte subsets (CD4+, CD8+, CD19+). Absolute changes from rest values were calculated and differences between conditions were determined through Chi-squared analysis with significance accepted at P <0.05. With regard to CD4+ and CD19+ lymphocytes, the interaction of caffeine and exercise did not affect naïve individuals to a greater extent immediately post exercise when compared to familiar, as similar apoptotic and migratory responses were observed (P >0.05). However, CD8+ lymphocyte cell death and migration responses were observed to be significantly greater at each sampling point in caffeine-familiar individuals (P <0.05). It is possible that chronic caffeine supplementation may prime CD8+ cell receptors for responsiveness to apoptosis and migration and the consequence of this form of immunosuppression in the post-exercise period should be determined.Entities:
Keywords: cytotoxic T cell; ergogenic supplement; exercise-induced lymphocytopenia; methylxanthine; programmed cell death
Mesh:
Substances:
Year: 2015 PMID: 26684634 PMCID: PMC5806713 DOI: 10.1177/0394632015612795
Source DB: PubMed Journal: Int J Immunopathol Pharmacol ISSN: 0394-6320 Impact factor: 3.219